Development of multifunctional molecules as potential therapeutic candidates for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis in the …

MG Savelieff, G Nam, J Kang, HJ Lee, M Lee… - Chemical …, 2018 - ACS Publications
Neurodegenerative diseases pose a substantial socioeconomic burden on society.
Unfortunately, the aging world population and lack of effective cures foreshadow a negative …

Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders

A Zhang, JL Neumeyer, RJ Baldessarini - Chemical reviews, 2007 - ACS Publications
Dopamine (DA) is a critical neurotransmitter in the mammalian central nervous system
(CNS). The cerebral dopaminergic system is implicated in the pathophysiology of several …

Recent advances in dopamine D2 receptor ligands in the treatment of neuropsychiatric disorders

R Juza, K Musilek, E Mezeiova… - Medicinal Research …, 2023 - Wiley Online Library
Dopamine is a biologically active amine synthesized in the central and peripheral nervous
system. This biogenic monoamine acts by activating five types of dopamine receptors (D1 …

Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents

AH Newman, P Grundt, MA Nader - Journal of medicinal chemistry, 2005 - ACS Publications
The stimulation of dopamine receptors via an increased concentration of synaptic dopamine
levels in the mesocorticolimbic regions of the brain has been defined as the primary …

Coordination assembly enables highly selective catalytic hydroaminomethylation of olefins

C Qian, Q Zheng, J Chen, B Tu, T Tu - Green Chemistry, 2023 - pubs.rsc.org
Hydroaminomethylation (HAM) of olefins constitutes one of the most promising and practical
methods to produce amines, but control of the selectivity between linear and branched …

Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds

AE Moritz, RB Free, DR Sibley - Cellular signalling, 2018 - Elsevier
Compounds that target D2-like dopamine receptors (DRs) are currently used as therapeutics
for several neuropsychiatric disorders including schizophrenia (antagonists) and …

[PDF][PDF] Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders

N Ye, JL Neumeyer, RJ Baldessarini, X Zhen, A Zhang - Chem. Rev, 2013 - academia.edu
Dopamine (DA) is a critical neurotransmitter in the mammalian central nervous system
(CNS). The cerebral dopaminergic system is implicated in the pathophysiology of several …

Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model

D Yedlapudi, GS Joshi, D Luo, SV Todi, AK Dutta - Scientific reports, 2016 - nature.com
Aggregation of alpha synuclein (α-syn) leading to dopaminergic neuronal death has been
recognized as one of the main pathogenic factors in the initiation and progression of …

Discovery of 4-(4-(2-((5-Hydroxy-1, 2, 3, 4-tetrahydronaphthalen-2-yl)(propyl) amino) ethyl) piperazin-1-yl) quinolin-8-ol and its analogues as highly potent dopamine …

B Ghosh, T Antonio, MEA Reith… - Journal of medicinal …, 2010 - ACS Publications
The role of iron in the pathogenesis of Parkinson's disease (PD) has been implicated
strongly because of generation of oxidative stress leading to dopamine cell death. In our …

Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification

Z Zhong, X He, J Ge, J Zhu, C Yao, H Cai, XY Ye… - European Journal of …, 2022 - Elsevier
Parkinson's disease (PD) is the second common neurodegenerative disease characterized
by movement disorder. The symptoms of PD harm both the physical and mental health of …